The DLBCL sample showed three distinct mutations: (1) TET2 p.Cys1298LeufsTer65 (c.3893delG), VAF = 18%; (2) TET2 p.H1382R (c.4145A > G), VAF = 35%; and (3) CBL p.R420Q (c.1259G > A), VAF = 10% (Table 1; Fig. 3). Here, TET2 is linked to diffuse large B-cell lymphoma.